Breakthrough Therapies Raise Manufacturing Issues - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Breakthrough Therapies Raise Manufacturing Issues



FDA officials are working with drug manufacturers to ensure that accelerated development of new breakthrough therapies yields high-quality products for patients. A risk is that evaluations based on limited stability data and “provisional” specifications could mask safety issues. These challenges were discussed at the November ISPE annual meeting, along with innovative manufacturing strategies that can accelerate quality production, such as continual manufacturing systems, using a clinical manufacturing site for initial commercial production, or producing clinical supplies in a commercial site.

Sarah Miksinski, acting director of the Division of New Drug Quality Assessment 2 in the Office of New Drug Quality Assessment, emphasized the importance of manufacturers discussing such options with the agency early in development so that the agency can anticipate a filing with limited data and form an appropriate CMC review team. Early discussion of development plans also permits FDA to assess the potential manufacturing site to determine if an inspection will be needed, while also learning of any new technologies or quality-by-design approaches.  

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here